Los Angeles Capital Management
KROS icon

Los Angeles Capital Management’s Keros Therapeutics KROS Stock Holding History

Los Angeles Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9M Buy
172,196
+138,425
+410% +$2.14M 0.01% 514
2025
Q4 		$508K Sell
33,771
-3,232
-9% -$56.7K ﹤0.01% 881
2025
Q3 		$585K Sell
37,003
-4,706
-11% -$69.5K ﹤0.01% 880
2025
Q2 		$557K Buy
+41,709
New +$563K ﹤0.01% 827

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Los Angeles Capital Management's KROS Position: Q1 2026 in Review

Los Angeles Capital Management increased its Keros Therapeutics (KROS) stake by 410% in Q1 2026, buying an estimated $2.14M and bringing the position to 172,196 shares worth $1.9M. The position accounts for 0.01% of the portfolio, ranked #514.

Los Angeles Capital Management first reported a position in KROS in Q2 2025 and has held it in 4 quarters since. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Los Angeles Capital Management held 172,196 shares of Keros Therapeutics worth $1.9M as of Q1 2026.
  • Los Angeles Capital Management bought 138,425 Keros Therapeutics shares in Q1 2026, an estimated $2.14M.
  • Keros Therapeutics made up 0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #514 holding.
  • Los Angeles Capital Management first reported a position in Keros Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.